- Gilead's Complera approved for HIV patients already on stable drug regimens
- ROUNDTABLE: Pharmacy’s future in sync with technology
- CVS Caremark study: More education needed on genetic testing in prescribing antiplatelet drugs
- Lipitor may be the first statin to switch to OTC
- FDA approves Bristol-Myers Squibb's, AstraZeneca's Farxiga
BURLINGTON, Mass. — The availability of new generic drugs for treating HIV will erode sales of HIV antiretroviral drugs into the next decade in developed countries, according to a new report.
Healthcare market research firm Decision Resources released the report Wednesday, showing that sales of antiretroviral drugs in the United States, France, Germany, the United Kingdom, Spain, Italy and Japan would be $13.1 billion in 2022, down from 2012's $13.4 billion.
Meanwhile, such single-tablet regimens as Atripla (efavirenz; emtricitabine; tenofovir) from Gilead Sciences and Bristol-Myers Squibb will drive sales in the future.